Symbols / TIVC Stock $1.33 +18.75% Tivic Health Systems, Inc.
TIVC (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in Fremont, California.
Ratings
- $TIVC stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Fri, 24 Apr 2026 14
- Tivic rebrands as Valion Bio, centering Entolimod and CDMO unit - Stock Titan hu, 23 Apr 2026 20
- Tivic Health Systems (TIVC) Stock Surges Over 24% After Hours: Here's What Is Happening - Sahm Fri, 24 Apr 2026 07
- Valauri buys Tivic Health (TIVC) shares worth $18,008 - Investing.com hu, 02 Apr 2026 07
- Insider Purchase: Director at $TIVC Buys 10,000 Shares - Quiver Quantitative Mon, 20 Apr 2026 20
- [EFFECT] Tivic Health Systems, Inc. SEC Filing - Stock Titan Wed, 15 Apr 2026 07
- Valion Bio (Nasdaq: TIVC) pivots to late-stage biopharma with Entolimod and CDMO - Stock Titan hu, 23 Apr 2026 20
- Tivic Health Systems Stock (TIVC) Opinions on Emerging Growth Conference Presentation - Quiver Quantitative hu, 02 Apr 2026 07
- TIVC SEC Filings - Tivic Health Systems Inc 10-K, 10-Q, 8-K Forms - Stock Titan ue, 21 Apr 2026 01
- TIVC | Tivic Health Systems, Inc. Insider Trading - Quiver Quantitative hu, 02 Apr 2026 14
- Tivic pitches a faster radiation treatment concept to U.S. War Tech Watch - Stock Titan Wed, 15 Apr 2026 07
- Tivic Health (TIVC) asks shareholders to OK 2.58M plan shares, Series C and $50M equity line - Stock Titan Mon, 20 Apr 2026 20
- Ukraine weighs Tivic radiation drug for emergency reserves - Stock Titan ue, 31 Mar 2026 07
- Biotech leader behind 17 drug launches now steering Tivic’s biopharma pivot - Stock Titan Wed, 04 Mar 2026 08
- Tumim may resell 956,222 Tivic shares; TIVC Purchase Agreement details (TIVC) - Stock Titan Wed, 15 Apr 2026 21
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
1.18
-36.09%
|
1.84
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
1.18
-36.09%
|
1.84
|
| Cost Of Revenue |
|
—
|
0.78
-12.49%
|
0.89
-42.31%
|
1.54
|
| Reconciled Cost Of Revenue |
|
—
|
0.78
-12.49%
|
0.89
-42.31%
|
1.54
|
| Gross Profit |
|
—
|
0.00
-99.30%
|
0.29
-4.01%
|
0.30
|
| Operating Expense |
|
7.90
+76.45%
|
4.48
-47.54%
|
8.53
-17.94%
|
10.40
|
| Research And Development |
|
3.13
+138.46%
|
1.31
-20.66%
|
1.66
-4.34%
|
1.73
|
| Selling General And Administration |
|
4.77
+50.71%
|
3.16
-54.01%
|
6.88
-20.65%
|
8.67
|
| Selling And Marketing Expense |
|
—
|
1.19
-44.14%
|
2.12
-23.89%
|
2.79
|
| General And Administrative Expense |
|
4.77
+50.71%
|
3.16
-33.44%
|
4.75
-19.11%
|
5.88
|
| Other Gand A |
|
4.77
+50.71%
|
3.16
-33.44%
|
4.75
-19.11%
|
5.88
|
| Total Expenses |
|
7.90
+76.45%
|
4.48
-52.49%
|
9.42
-21.08%
|
11.94
|
| Operating Income |
|
-7.90
-76.45%
|
-4.48
+45.71%
|
-8.24
+18.35%
|
-10.10
|
| Total Operating Income As Reported |
|
-7.90
-76.45%
|
-4.48
+45.71%
|
-8.24
+18.35%
|
-10.10
|
| EBITDA |
|
-7.84
-90.43%
|
-4.12
+48.93%
|
-8.06
+18.75%
|
-9.92
|
| Normalized EBITDA |
|
-7.87
-91.11%
|
-4.12
+48.93%
|
-8.06
+18.75%
|
-9.92
|
| Reconciled Depreciation |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| EBIT |
|
-7.85
-75.55%
|
-4.47
+45.79%
|
-8.24
+18.35%
|
-10.10
|
| Total Unusual Items |
|
0.03
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.03
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Pretax Income |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Non Operating Interest Income Expense |
|
-0.12
-2150.00%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Interest Expense Non Operating |
|
0.15
|
0.00
|
—
|
—
|
| Net Interest Income |
|
-0.12
-2150.00%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Interest Expense |
|
0.15
|
0.00
|
—
|
—
|
| Interest Income Non Operating |
|
0.02
+283.33%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Interest Income |
|
0.02
+283.33%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Other Income Expense |
|
0.03
|
—
|
—
|
—
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
0.03
|
—
|
—
|
—
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Income From Continuing And Discontinued Operation |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Net Income Continuous Operations |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Income Discontinuous Operations |
|
-0.89
+25.32%
|
-1.19
|
—
|
—
|
| Normalized Income |
|
-8.02
-79.44%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Income Common Stockholders |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Diluted EPS |
|
—
|
-19.68
+88.87%
|
-176.80
+90.00%
|
-1,768.00
|
| Basic EPS |
|
—
|
-19.68
+88.87%
|
-176.80
+90.00%
|
-1,768.00
|
| Basic Average Shares |
|
—
|
0.29
+516.01%
|
0.05
+720.00%
|
0.01
|
| Diluted Average Shares |
|
—
|
0.29
+516.01%
|
0.05
+720.00%
|
0.01
|
| Diluted NI Availto Com Stockholders |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-0.00
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
5.16
|
| Current Assets |
|
4.65
|
| Cash Cash Equivalents And Short Term Investments |
|
3.40
|
| Cash And Cash Equivalents |
|
3.40
|
| Receivables |
|
0.17
|
| Accounts Receivable |
|
0.17
|
| Gross Accounts Receivable |
|
—
|
| Allowance For Doubtful Accounts Receivable |
|
—
|
| Inventory |
|
0.76
|
| Raw Materials |
|
0.75
|
| Work In Process |
|
0.00
|
| Finished Goods |
|
0.04
|
| Prepaid Assets |
|
—
|
| Current Deferred Assets |
|
0.00
|
| Assets Held For Sale Current |
|
—
|
| Other Current Assets |
|
0.33
|
| Total Non Current Assets |
|
0.51
|
| Net PPE |
|
0.47
|
| Gross PPE |
|
0.51
|
| Accumulated Depreciation |
|
-0.04
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.35
|
| Machinery Furniture Equipment |
|
0.01
|
| Other Properties |
|
0.15
|
| Goodwill And Other Intangible Assets |
|
—
|
| Other Intangible Assets |
|
—
|
| Non Current Deferred Assets |
|
0.00
|
| Other Non Current Assets |
|
0.03
|
| Total Liabilities Net Minority Interest |
|
1.58
|
| Current Liabilities |
|
1.40
|
| Payables And Accrued Expenses |
|
1.21
|
| Payables |
|
0.87
|
| Accounts Payable |
|
0.71
|
| Current Accrued Expenses |
|
0.34
|
| Total Tax Payable |
|
0.16
|
| Current Debt And Capital Lease Obligation |
|
0.19
|
| Current Capital Lease Obligation |
|
0.19
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.18
|
| Liabilities Heldfor Sale Non Current |
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
0.18
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
0.18
|
| Other Non Current Liabilities |
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
3.58
|
| Common Stock Equity |
|
3.58
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.09
|
| Ordinary Shares Number |
|
0.09
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
41.47
|
| Retained Earnings |
|
-37.89
|
| Total Equity Gross Minority Interest |
|
3.58
|
| Total Capitalization |
|
3.58
|
| Working Capital |
|
3.25
|
| Invested Capital |
|
3.58
|
| Total Debt |
|
0.37
|
| Capital Lease Obligations |
|
0.37
|
| Net Tangible Assets |
|
3.58
|
| Tangible Book Value |
|
3.58
|
| Derivative Product Liabilities |
|
—
|
| Inventories Adjustments Allowances |
|
-0.03
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.00
-22.25%
|
-5.72
+32.73%
|
-8.51
+4.57%
|
-8.92
|
| Cash Flow From Continuing Operating Activities |
|
-6.62
-30.24%
|
-5.08
+40.29%
|
-8.51
+4.57%
|
-8.92
|
| Cash From Discontinued Operating Activities |
|
-0.38
+40.90%
|
-0.64
|
—
|
—
|
| Net Income From Continuing Operations |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Depreciation Amortization Depletion |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| Depreciation |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| Depreciation And Amortization |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| Other Non Cash Items |
|
0.24
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.56
+146.29%
|
0.23
-15.50%
|
0.27
-31.91%
|
0.40
|
| Provisionand Write Offof Assets |
|
—
|
0.35
+1006.25%
|
0.03
|
0.00
|
| Asset Impairment Charge |
|
0.14
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
-0.03
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-0.03
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.45
+137.89%
|
-1.19
-58.64%
|
-0.75
-224.30%
|
0.60
|
| Change In Receivables |
|
—
|
0.10
+256.72%
|
-0.07
-6800.00%
|
0.00
|
| Changes In Account Receivables |
|
—
|
0.10
+256.72%
|
-0.07
-6800.00%
|
0.00
|
| Change In Inventory |
|
—
|
0.08
+10.67%
|
0.07
+117.28%
|
-0.43
|
| Change In Prepaid Assets |
|
0.08
+0.00%
|
0.08
+184.78%
|
-0.09
-116.49%
|
0.56
|
| Change In Payables And Accrued Expense |
|
0.37
+139.96%
|
-0.94
-84.62%
|
-0.51
-178.85%
|
0.64
|
| Change In Accrued Expense |
|
0.23
+167.53%
|
-0.35
-437.86%
|
0.10
-5.50%
|
0.11
|
| Change In Payable |
|
0.14
+123.64%
|
-0.59
+3.61%
|
-0.61
-214.23%
|
0.53
|
| Change In Account Payable |
|
0.14
+123.64%
|
-0.59
+3.61%
|
-0.61
-214.23%
|
0.53
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
0.03
|
0.00
-100.00%
|
0.01
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.37
-129.19%
|
-0.16
+9.55%
|
-0.18
|
| Investing Cash Flow |
|
-0.70
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
-0.70
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Net PPE Purchase And Sale |
|
-0.04
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Purchase Of PPE |
|
-0.04
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Capital Expenditure |
|
-0.58
|
—
|
-0.12
-972.73%
|
-0.01
|
| Net Investment Purchase And Sale |
|
-0.12
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-0.12
|
0.00
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
-0.54
|
0.00
|
—
|
—
|
| Purchase Of Intangibles |
|
-0.54
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
18.35
+323.52%
|
4.33
-49.08%
|
8.51
+1711.17%
|
-0.53
|
| Cash Flow From Continuing Financing Activities |
|
18.35
+323.52%
|
4.33
-49.08%
|
8.51
+1711.17%
|
-0.53
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
2.34
-46.66%
|
4.38
-48.50%
|
8.51
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.11
|
0.00
|
0.00
-100.00%
|
0.06
|
| Net Other Financing Charges |
|
-0.31
-528.57%
|
-0.05
|
—
|
-0.58
|
| Changes In Cash |
|
10.64
+864.03%
|
-1.39
-1041.80%
|
-0.12
+98.71%
|
-9.46
|
| Beginning Cash Position |
|
2.00
-41.03%
|
3.40
-3.47%
|
3.52
-72.89%
|
12.97
|
| End Cash Position |
|
12.64
+531.62%
|
2.00
-41.03%
|
3.40
-3.47%
|
3.52
|
| Free Cash Flow |
|
-7.58
-32.40%
|
-5.72
+33.65%
|
-8.63
+3.37%
|
-8.93
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
2.34
-46.66%
|
4.38
-48.50%
|
8.51
|
0.00
|
| Issuance Of Capital Stock |
|
18.55
+323.33%
|
4.38
-48.50%
|
8.51
|
0.00
|
| Net Preferred Stock Issuance |
|
16.21
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
16.21
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-23 View
- 42026-04-20 View
- 42026-04-02 View
- 10-K2026-03-30 View
- 8-K2026-03-25 View
- 8-K2026-03-20 View
- 42026-03-19 View
- 8-K2026-03-13 View
- 8-K2026-03-11 View
- 8-K2026-03-04 View
- 42026-02-20 View
- 8-K2026-02-09 View
- 8-K2026-01-20 View
- 42025-12-22 View
- 42025-12-22 View
- 8-K2025-12-11 View
- 8-K2025-11-18 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 8-K2025-11-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|